New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results
The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.